Clinical trials: Infection Risk
HIV, Cardiovascular Disease
Does Rosuvastatin Delay Progression of Atherosclerosis in HIV
This study is a randomised double blind placebo controlled trial comparing Rosuvastatin with placebo in HIV positive people who are at intermediate cardiovascular risk.
- Trial name
- NCT01813357
- Testing
- Rosuvastatin
- Where
- 2 sites in Australia, Switzerland
- Volunteers
- 84 people
- Sponsor
- Bayside Health
Influenza, Vaccination
Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake
The study team previously demonstrated that patients are more likely to receive flu vaccine after learning that they are at high risk for flu complications.
- Conditions
- Influenza, Vaccination, Health Promotion, Health Behavior
- Trial name
- NCT05009251
- Testing
- Reminder, Risk reduction, Medical records-based recommendation
- Where
- United States
- Volunteers
- 45,061 people
- Sponsor
- National Bureau of Economic Research, Inc.
Recurrent B Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia
Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia
This phase I trial studies the side effects and best dose of blinatumomab when given with nivolumab alone or nivolumab and ipilimumab in treating patients with poor-risk CD19+ precursor B-lymphoblastic leukemia that has come back…
- Conditions
- Recurrent B Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory B Acute Lymphoblastic Leukemia, Refractory Mixed Phenotype Acute Leukemia
- Trial name
- NCT02879695
- Testing
- Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration and Biopsy
- Where
- 7 sites in United States
- Volunteers
- 28 people
- Sponsor
- National Cancer Institute (NCI)
Pneumonitis, Nonsmall Cell Lung Cancer Stage III
Exhaled Breath Analysis to Predict Risk of Symptomatic Pneumonitis
This is a prospective pilot study investigating exhaled breath condensate analyses to quantify the variability over time of various biomarkers associated with symptomatic pneumonitis.
- Trial name
- NCT04040244
- Testing
- Exhaled Breath Collection, Blood sample
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Wake Forest University Health Sciences
Invasive Fungal Infections
Open, Non Comparative Study Of Voriconazole In Slovak Patients With Very High Risk Of Developing An Invasive Fungal Infection
Assessment of safety and efficacy of voriconazole in real-life setting in the treatment of high risk patients with invasive fungal infections. The study is conducted in Slovakia only.
- Trial name
- Ve-RIFI (NCT01137292)
- Testing
- voriconazole (VFEND®)
- Volunteers
- 177 people
- Sponsor
- Pfizer
Shoulder Infection
Skin Prep to Reduce Postoperative Shoulder Infection
Propionibacterium acnes is the most common pathogen identified from a surgical site infection in the shoulder. Standard skin preps do not prevent this type of infection.
- Trial name
- NCT02510144
- Testing
- Skin Prep Chlorhexidine, Skin Prep Benzoyl Peroxide
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Maryland, Baltimore
Heart Defects, Congenital, Hyperglycemia
SPECS: Safe Pediatric Euglycemia in Cardiac Surgery
Critically ill children, including children undergoing heart surgery, commonly develop elevated blood glucose (also known as "blood sugar") levels during their illness, which can lead to poor health outcomes and an increased risk…
- Trial name
- SPECS (NCT00443599)
- Testing
- Insulin, Usual Care
- Where
- 2 sites in United States
- Volunteers
- 989 people
- Sponsor
- Boston Children's Hospital
Influenza
Safety, PK and Effectiveness of IV Peramivir in Elderly and Higher Risk Subjects With Uncomplicated Influenza
This study will evaluate the safety, pharmacokinetics and effectiveness of a single dose of 600 mg IV peramivir in the treatment of elderly subjects with acute uncomplicated influenza infection and in subjects with acute…
- Trial name
- NCT02635724
- Testing
- Peramivir
- Where
- 15 sites in United States
- Volunteers
- 74 people
- Sponsor
- BioCryst Pharmaceuticals
Human Immunodeficiency Virus
Feasibility of Short-Term PrEP Uptake for MSM With Episodic High-Risk for HIV
This study is designed to investigate the acceptability, perceived need and uptake of short-term episodic Pre-Exposure Prophylaxis (PrEP) for HIV prevention among men who have sex with men (MSM).
- Trial name
- NCT02495779
- Testing
- emtricitabine/tenofovir, CBT-based counseling
- Where
- 2 sites in United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- James Egan
HIV/AIDS
Using Open Contest and Neuro-influence Experiment to Develop and Evaluate PrEP Promotion Messages for High Risk Men
The aim of this study is to examine the utility of neuroimaging technique to evaluate pre-exposure prophylaxis (PrEP) promotion messages for men who have sex with men (MSM) at risk of HIV in Baltimore.
- Trial name
- NCT04166851
- Testing
- PrEP campaign messages developed via open contest, PrEP campaign messages developed via social marketing approach
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
HIV Infections
Young Men's Health Project Targeting HIV Risk Reduction and Substance Abuse
YMHP is a counseling intervention program for which the goals are to better understand HIV-prevention focused self-management behaviors among HIV-negative YMSM, and to study the implementation of YMHP to improve portability and…
- Trial name
- YMHP (NCT03577301)
- Testing
- Clinic-based Delivery, Remote Delivery, Multi-modal Delivery
- Where
- 3 sites in United States
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Florida State University
HIV-infection/AIDS
WeExPAnd: PrEP Demonstration Project Among Women at Risk for HIV Infection - Preexposure Prophylaxis (PrEP)
The objective of this application is to increase PrEP uptake among women vulnerable to HIV acquisition in the rural South, specifically those seeking care at Federally Qualified Healthcare Centers (FQHC) in rural Alabama.
- Trial name
- PrEP (NCT04373551)
- Testing
- Cultural adaptation of a patient-provider communication tool
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- University of Alabama at Birmingham
COVID-19
Study of the Safety, Tolerability and Efficacy of NP-101 in Treating High Risk Participants Who Are Covid-19 Positive.
The goal of this clinical trial is to evaluate the safety, tolerability, and efficacy of NP-101 in treating high-risk participants who have tested positive for Covid-19.
- Trial name
- BOSS-002 (NCT05785390)
- Testing
- NP-101
- Where
- 4 sites in United States
- Volunteers
- 170 people
- Sponsor
- Novatek Pharmaceuticals
Hepatitis C, Medication Adherence
Intensive Models of HCV Care for Injection Drug Users
Injection drug users (IDUs) constitute 60% of the approximately 5 million people in the U.S. infected with hepatitis C virus (HCV). HCV treatment leading to sustained viral response (SVR) is associated with increased survival.
- Trial name
- NCT01857245
- Testing
- Intensive Models (mDOT and CGT) of HCV Care
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Prisma Health-Upstate
COVID-19 (Coronavirus Disease 2019)
A US Study to Look at Loss of Work and Healthcare Costs for People Affected With Mild-to-moderate COVID 19 Who Have High Chances of the Disease Becoming Severe
The purpose of this study is to understand how COVID-19 affects people's ability to work and to calculate the costs associated with loss of work.
- Trial name
- NCT07072793
- Testing
- nirmatrelvir-ritonavir
- Where
- United States
- Volunteers
- 131,005 people
- Sponsor
- Pfizer
Respiratory Syncytial Virus Infections
Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children
The primary objective of this study was to compare the safety and efficacy of motavizumab to palivizumab when administered monthly by intramuscular (IM) injection for the reduction of the incidence of RSV hospitalization among…
- Trial name
- NCT00129766
- Testing
- motavizumab (MEDI-524), palivizumab
- Where
- 344 sites in United States, Argentina and 22 more
- Volunteers
- 6,635 people
- Sponsor
- MedImmune LLC
Human Immunodeficiency Virus Infection
Mechanisms of Immune Reconstitution & Reduced Immune Activation Following Darunavir-based ART
Potent HIV suppression with Darunavir-based antiretroviral therapy (ART) will lead to repopulation of gastrointestinal-associated lymphoid tissue (GALT) cluster of differentiation (CD)4+ T-cell populations, normalization of…
- Trial name
- NCT01869634
- Testing
- darunavir with ritonavir and fixed-dose viread+emtricitabine daily
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
Colorectal Cancer Screening
Facilitators and Barriers to Cancer Screening: Stakeholder Perspectives on Implementation
The rate of screening for colorectal cancer (CRC) in the U.S. remains low (under 65%), meaning that thousands of people die of colorectal cancer unnecessarily.
- Trial name
- NCT04683744
- Testing
- Semi-structured interviews-Patients, Semi-structured interviews-Health system
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- Indiana University
Respiratory Syncytial Virus Infections
A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults 60 Years of Age and Above
The aim of this study is to demonstrate the immune response and to evaluate the safety of the RSVPreF3 OA investigational vaccine in non-immunocompromised adults 18-49 years of age (YOA), who are at increased risk (AIR) for RSV…
- Trial name
- NCT06389487
- Testing
- RSVPreF3 OA investigational vaccine
- Where
- 52 sites in United States, Australia and 4 more
- Volunteers
- 1,459 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cytomegalovirus Disease
Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for Cytomegalovirus Infection
The purpose of the study is to assess the incidence and severity of late Cytomegalovirus (CMV) disease, defined as CMV syndrome or tissue invasive disease occurring between 100 and 200 days and after 200 days post-transplant in…
- Trial name
- NCT01509404
- Testing
- Valganciclovir, CMV hyperimmune globulin
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Medical University of South Carolina